Tags: biotechpatientpharmaPolicy & Regulationpolicy-regulation
Profile | Contacts | Recent Articles on Subject | |
---|---|---|---|
1 | Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia | ||
2 | John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California | Andrew Caldwell - 8 months ago | |
3 | Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland | ||
4 | Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA | ||
5 | Lizzy Lawrence STAT News Medical devices reporter at STATnews. Loves news tips. | ||
6 | Katie Adams MedCity News Editor. Exeter, New Hampshire | ||
7 | Natasha Lomas TechCrunch Journalist. Climber-in-training. Owns cats. Barcelona and London | ||
8 | Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts | STAT+: Alnylam versus BridgeBio: The ATTR-CM debate - 2 months ago STAT+: Amylyx ALS drug failure leaves patients, advocates, and researchers reeling — and wondering what’s next - 8 months ago | |
9 | Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. | STAT+: Can amylin drugs best Wegovy and Zepbound? Companies bet on next big obesity target - 2 months ago STAT+: Startup launches with $245 million for twice yearly asthma treatment - about 1 year ago | |
10 | Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois | STAT+: Can amylin drugs best Wegovy and Zepbound? Companies bet on next big obesity target - 2 months ago It’s happy hour (for now) for Alnylam - 4 months ago |